This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Medivation Prostate Cancer Drug Launches Hot

SAN FRANCISCO ( TheStreet) -- Medivation's (MDVN - Get Report) marketing partner Astellas reported Xtandi sales of $14 million for the third quarter and forecast $100 million in sales for the newly launched prostate cancer drug through the end of its fiscal year on March 31, 2013.

Xtandi was developed by Medivation but is being sold by the Japanese drug maker Astellas, which reports sales.

Gauging a consensus for early Xtandi sales has been difficult but $14 million in third-quarter revenue is definitely higher than the Street expected given that Astellas only started selling the drug in the middle of September. Assume that a good chunk of third-quarter sales is wholesaler inventory stocking.

The guidance for $100 million in Xtandi sales through March 31, 2013 -- or six months into the drug's launch -- puts the drug on pace to meet Street expectations for the calendar year 2013.

"Taking into consideration potential sales ramp, Astellas' guidance could imply Oct.-Dec. 2012 sales of $30-35 million and Jan.-March 2013 sales of $51-56 million, favorably positioning Xtandi to at least meet expectations including consensus of approximately $225M, which includes estimates in the mid-$300 millions that we believe are bullish for the first-year of launch for any product," writes Jefferies analyst Biren Amin.

FDA approved Xtandi in August for the post-chemo treatment of men with advanced prostate cancer. In this setting, Xtandi competes mainly with Johnson & Johnson's (JNJ - Get Report) Zytiga. Both drugs, however, are expected to eventually garner most of their sales in the larger and more lucrative pre-chemo prostate cancer setting, where they also threaten to replace Dendreon's (DNDN) Provenge.

--Written by Adam Feuerstein in Boston.



>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein.

>To submit a news tip, send an email to: tips@thestreet.com.

Follow TheStreet on Twitter and become a fan on Facebook.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
DNDN $0.06 -6.02%
JNJ $102.80 1.57%
MDVN $119.74 5.18%
AAPL $130.42 1.26%
FB $80.41 1.07%

Markets

DOW 18,214.42 -10.15 -0.06%
S&P 500 2,110.74 -3.12 -0.15%
NASDAQ 4,987.89 +20.7530 0.42%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs